Trypanosoma cruzi trans-sialidase as a drug target against Chagas disease (American trypanosomiasis)

Future Medicinal Chemistry

Volumn 5, Issue 15, 2013, Pages 1889-1900

  Miller Iii, Bill R ^a   Roitberg, Adrian E ^a  

^a University of Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIFLUOROMETHYL 4 NITROPHENYL 3,5 DIDEOXY DEXTRO GLYCERO ALPHA DEXTRO GALACTO 2 NONULOPYRANOSID ACID; 6 CHLORO 9,10 DIHYDRO 4,5,7 TRIHYDROXYANTHRACENECARBOXYLIC ACID; ANTIPROTOZOAL AGENT; LACTOSE; N ACETYL 2,3 DIDEHYDRO 2 DEOXYNEURAMINIC ACID; SIALIC ACID; SIALIDASE; SIALIDASE INHIBITOR; SIALYLLACTOSE; UNCLASSIFIED DRUG;

CHAGAS DISEASE; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PARASITE SURVIVAL; PRIORITY JOURNAL; PROTIST LIFE CYCLE STAGE; QUANTUM MECHANICS; REVIEW; TRYPANOSOMA CRUZI;

BINDING SITES; CATALYTIC DOMAIN; CHAGAS DISEASE; DRUG DESIGN; ENZYME INHIBITORS; GLYCOPROTEINS; HUMANS; MOLECULAR DOCKING SIMULATION; NEURAMINIDASE; SUBSTRATE SPECIFICITY; TRYPANOSOMA CRUZI;

EID: 84886514337     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.129     Document Type: Review

References (73)

1. Chagas C. Nova tripanozomiaze humana: Estudos sobre a morfolojia eo ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem. Inst. Oswaldo Cruz. 1, 159-218 (1909
2. WHO, Chagas disease (American trypanosomiasis), fact sheet 340. WHO Press, Geneva, Switzerland (2010
3. Hotez PJ, Dumonteil E, Woc-Colburn L et al. Chagas disease: 'the new HIV/AIDS of the Americas'. PLoS Negl. Trop. Dis. 6(5), e1498 (2012
4. Chagas C, Chagas C. Tripanosomiase americana: Forma aguda da molestia. Mem. Inst. Oswaldo Cruz. 8(2), 37-60 (1916
5. Chagas C, Villela E. Forma cardíaca da trypanosomiase Americana. Mem. Inst. Oswaldo Cruz. 14. 5-61 (1922
6. Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz. 97(1), 3-24 (2002
7. Castro JA, deMecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American Trypanosomiasis). Hum. Exp. Toxicol. 25(8), 471-479 (2006
8. Brener Z. Biology of Trypanosoma cruzi. Annu. Rev. Microbiol. 27, 347-382 (1973
9. Tyler KM, Engman DM. The life cycle of Trypanosoma cruzi revisited. Int. J. Parasitol. 31(5-6), 472-480 (2001
10. Andrews NW. Living dangerously: How Trypanosoma cruzi uses lysosomes to get inside host cells, and then escapes into the cytoplasm. Biol. Res. 26(1-2), 65-67 (1993
11. Previato J, Andrade AFB, Pessolani MCV, Mendonça-Previato L. Incorporation of sialic acid into Trypanosoma cruzi macromolecules. A proposal for a new metabolic route. Mol. Biochem. Parasit. 16(1), 85-96 (1985
12. Pilatte Y, Bignon J, Lambré CR. Sialic acids as important molecules in the regulation of the immune system: Pathophysiological implications of sialidases in immunity. Glycobiology 3(3), 201-218 (1993
13. Dc-Rubin SSC, Schenkman S. Trypanosoma cruzi trans-sialidase as a multifunctional enzyme in Chagas' disease. Cell. Microbiol. 14(10), 1522-1530 (2012
14. Schenkman RP, Vandekerckhove F, Schenkman S. Mammalian cell sialic acid enhances invasion by Trypanosoma cruzi. Infect. Immun. 61(3), 898-902 (1993
15. Schenkman S, Jiang M-S, Hart GW, Nussenzweig V. A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells. Cell 65(7), 1117-1125 (1991
16. Frasch AC. Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi. Parasitol. Today 16(7), 282-286 (2000
17. Cremona ML, Sánchez DO, Frasch ACC, Campetella O. A single tyrosine differentiates active and inactive Trypanosoma cruzi trans-sialidases. Gene 160(1), 123-128 (1995
18. Mendonça-Previato L, Todeschini AR, Freire-de-Lima L, Previato JO. The trans-sialidase from Trypanosoma cruzi a putative target for trypanocidal agents. Open Parasitol. J. 4, 111-115 (2010
19. Buschiazzo A, Amaya MF, Amaya ML, Frasch AC, Alzari PM. The crystal structure and mode of action of trans-sialidase, a key enzyme in Trypanosoma cruzi pathogenesis. Mol. Cell 10(4), 757-768 (2002
20. Amaya MF, Watts AG, Damager I, et al. Structural insights into the catalytic mechanism of Trypanosoma cruzi trans-sialidase. Structure 12(5), 775-784 (2004
21. Bruner M. Mechanistic variation in the glycosyltransfer of N-Acetylneuraminic acid. Nukleonika 47(1), S25-S28 (2002
22. Watts AG, Damager I, Amaya ML, et al. Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: Tyrosine is the catalytic nucleophile. J. Am. Chem. Soc. 125(25), 7532-7533 (2003
23. Damager I, Buchini S, Amaya MF et al. Kinetic and mechanistic analysis of Trypanosoma cruzi trans-sialidase reveals a classical ping-pong mechanism with acid/base catalysis. Biochemistry 47(11), 3507-3512 (2008
24. Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des. 15(5), 411-428 (2001
25. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267(3), 727-748 (1997
26. Morris GM, Goodsell DS, Halliday RS et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comp. Chem. 19(14), 1639-1662 (1998
27. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comp. Chem. 31(2), 455-461 (2010
28. Friesner RA, Banks JL, Murphy RB, et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47(7), 1739-1749 (2004
29. Bissantz C, Folkers G, Rognan D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J. Med. Chem. 43(25), 4759-4767 (2000
30. Chen H, Lyne PD, Giordanetto F, Lovell T, Li J. On evaluating molecular-docking methods for pose prediction and enrichment factors. J. Chem. Inf. Model. 46(1), 401-415 (2006
31. Cheng T, Li X, Li Y, Liu Z, Wang R. Comparative assessment of scoring functions on a diverse test set. J. Chem. Inf. Model. 49(4), 1079-1093 (2009
32. 2Cross JB, Thompson DC, Rai BK, et al. Comparison of several molecular docking programs: Pose prediction and virtual screening accuracy. J. Chem. Inf. Model. 49(6), 1455-1474 (2009
33. Fersht A. Structure and mechanism in protein science: A guide to enzyme catalysis and protein folding. W.H.Freeman & Co Ltd, NY, USA (1998
34. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65(3), 712-725 (2006
35. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-Atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118(45), 11225-11236 (1996
36. Patel S, Mackerell AD, Brooks CL. CHARMM fluctuating charge force field for proteins: II protein/solvent properties from molecular dynamics simulations using a nonadditive electrostatic model. J. Comp. Chem. 25(12), 1504-1514 (2004
37. Oostenbrink C, Villa A, Mark AE, Van Gunsteren WF. A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force-field parameter sets 53A5 and 53A6. J. Comp. Chem. 25(13), 1656-1676 (2004
38. Warshel A, Levitt M. Theoretical studies of enzymic reactions: Dielectric, electrostatic and steric stabilization of the carbonium ion in the reaction of lysozyme. J. Mol. Biol. 103(2), 227-249 (1976
39. Senn HM, Thiel W. QM/MM methods for biomolecular systems. Angew. Chem. Int. Ed. 48(7), 1198-1229 (2009
40. Gohlke H, Kiel C, Case DA. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J. Mol. Biol. 330(4), 891-913 (2003
41. Zoete V, Meuwly M, Karplus M. Study of the insulin dimerization: Binding free energy calculations and per-residue free energy decomposition. Proteins 61(1), 79-93 (2005
42. Chachra R, Rizzo RC. Origins of resistance conferred by the R292K neuraminidase mutation via molecular dynamics and free energy calculations. J. Chem. Theory Comput. 4(9), 1526-1540 (2008
43. Torrie GM, Valleau JP. Monte Carlo free energy estimates using non-Boltzmann sampling: Application to the sub-critical Lennard-Jones fluid. Chem. Phys. Lett. 28(4), 578-581 (1974
44. Roux B. The calculation of the potential of mean force using computer simulations. Comput. Phys. Commun. 91(1-3), 275-282 (1995
45. Demir O, Roitberg AE. Modulation of catalytic function by differential plasticity of the active site: Case study of Trypanosoma cruzi trans-sialidase and Trypanosoma rangeli sialidase. Biochemistry 48(15), 3398-3406 (2009
46. Amaro RE, Schnaufer A, Interthal H, Hol W, Stuart KD, McCammon JA. Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei. Proc. Natl Acad. Sci. USA 105(45), 17278-17283 (2008
47. Damm KL, Ung PMU, Quintero JJ, Gestwicki JE, Carlson HA. A poke in the eye: Inhibiting HIV-1 protease through its flap-recognition pocket. Biopolymers 89(8), 643-652 (2008
48. Pierdominici-Sottile G, Horenstein NA, Roitberg AE. Free energy study of the catalytic mechanism of Trypanosoma cruzi trans-sialidase. From the michaelis complex to the covalent intermediate. Biochemistry 50(46), 10150-10158 (2011
49. Pauling L. Molecular architecture and biological reactions. Chem. Eng. News Arch. 24(10), 1375-1377 (1946
50. Pauling L. Nature of forces between large molecules of biological interest. Nature 161(4097), 707-709 (1948
51. Pierdominici-Sottile G, Roitberg AE. Proton transfer facilitated by ligand binding. An energetic analysis of the catalytic mechanism of Trypanosoma cruzi trans-sialidase. Biochemistry 50(5), 836-842 (2011
52. Raha K, Peters MB, Wang B, et al. The role of quantum mechanics in structure-based drug design. Drug Discov. Today 12(17-18), 725-731 (2007
53. Meindl P, Bodo G, Palese P, Schulman J, Tuppy H. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-Acetylneuraminic acid. Virology 58(2), 457-463 (1974
54. Vandekerckhove F, Schenkman S, Carvalho LPDE et al. Substrate specificity of the Trypanosoma cruzi trans-sialidase. Glycobiology 2(6), 541-548 (1992
55. Paris G, Ratier L, Amaya MF, Nguyen T, Alzari PM, Frasch ACC. A sialidase mutant displaying trans-sialidase activity. J. Mol. Biol. 345(4), 923-934 (2005
56. Streicher H. Inhibition of microbial sialidases-what has happened beyond the influenza virus? Curr. Med. Chem. Anti-Infect. Agents 3(2), 149-161 (2004
57. Harrison JA, Kartha KPR, Turnbull WB et al. Hydrolase and sialyltransferase activities of Trypanosoma cruzi trans-sialidase towards NeuAc-A-2,3-Gal-b-O-PNP. Bioorg. Med. Chem. Lett. 11(2), 141-144 (2001
58. Buchini S, Buschiazzo A, Withers SG. A new generation of specific Trypanosoma cruzi trans-sialidase inhibitors. Angew. Chem. Int. Ed. 120(14), 2740-2743 (2008
59. Carvalho ST, Sola-Penna M, Oliveira IA, et al. A new class of mechanism-based inhibitors for Trypanosoma cruzi trans-sialidase and their influence on parasite virulence. Glycobiology 20(8), 1034-1045 (2010
60. Agusti R, Paris G, Ratier L, Frasch ACC, de Lederkremer RM. Lactose derivatives are inhibitors of Trypanosoma cruzi trans-sialidase activity toward conventional substrates in vitro and in vivo. Glycobiology 14(7), 659-670 (2004
61. Giorgi ME, Ratier L, Agusti R, Frasch ACC, Lederkremer RMd. Synthesis of PEGylated lactose analogs for inhibition studies on T. cruzi trans-sialidase. Glycoconj. J. 27(5), 549-559 (2010
62. Giorgi ME, Piuselli D, Agusti R, de Lederkremer RM, Giordano S. Synthesis of oseltamivir conjugates with lactose analogs for inhibition studies on Trypanosoma cruzi trans-sialidase. Arkivoc 7, 260-271 (2011
63. Kolb HC, Finn MG, Sharpless KB. Click chemistry: Diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 40(11), 2004-2021 (2001
64. Carvalho I, Andrade P, Campo VL et al. 'Click chemistry' synthesis of a library of 1,2,3-Triazole-substituted galactose derivatives and their evaluation against Trypanosoma cruzi and its cell surface trans-sialidase. Bioorg. Med. Chem. 18(7), 2412-2427 (2010
65. Harrison JA, Kartha KPR, Fournier EJL, et al. Probing the acceptor substrate binding site of Trypanosoma cruzi trans-sialidase with systematically modified substrates and glycoside libraries. Org. Biomol. Chem. 9(5), 1653 (2011
66. Meinke S, Schroven A, Thiem J. Sialic acid C-glycosides with aromatic residues: Investigating enzyme binding and inhibition of Trypanosoma cruzi trans-sialidase. Org. Biomol. Chem. 9(12), 4487-4497 (2011
67. Neres J, Bonnet P, Edwards PN, et al. Benzoic acid and pyridine derivatives as inhibitors of Trypanosoma cruzi trans-sialidase. Bioorg. Med. Chem. 15(5), 2106-2119 (2007
68. Neres J, Brewer ML, Ratier L, et al. Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening. Bioorg. Med. Chem. Lett. 19(3), 589-596 (2009
69. Kim JH, Ryu HW, Shim JH, Park KH, Withers SG. Development of new and selective Trypanosoma cruzi trans-sialidase inhibitors from sulfonamide chalcones and their derivatives. ChemBioChem 10(15), 2475-2479 (2009
70. Lima AH, Lameira J, Alves CN. Protein-ligand interaction of T. cruzi trans-sialidase inhibitors: A docking and QM/MM MD study. Struct. Chem. 23(1), 147-152 (2012
71. Arioka S, Sakagami M, Uematsu R et al. Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase. Bioorg. Med. Chem. 18(4), 1633-1640 (2010
72. Buschiazzo A, Muiá R, Larrieux N, Pitcovsky T, Mucci J, Campetella O. Trypanosoma cruzi trans-sialidase in complex with a neutralizing antibody: Structure/function studies towards the rational design of inhibitors. PLoS Pathog. 8(1), e1002474 (2012
73. Paris G, Cremona ML, Amaya MF et al. Probing molecular function of trypanosomal sialidases: Single point mutations can change substrate specificity and increase hydrolytic activity. Glycobiology 11(4), 305-311 (2001